|drug298||Connor-Davidson Resilience Scale 10 items (CD-RISC 10) Wiki||0.71|
|drug572||Impact of Event Scale-Revised Wiki||0.71|
|drug185||Brief Psychiatric Rating Scale Wiki||0.71|
|drug359||Depression, Anxiety and Stress Scale Wiki||0.71|
|D000066553||Problem Behavior NIH||1.00|
|D001523||Mental Disorders NIH||0.58|
|D009461||Neurologic Manifestations NIH||0.41|
There are 2 clinical trials
Given the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with psychiatric disorders and suspected of infection, hospitalized in a specific unit, at the psychiatric, somatic and pharmacological level.
Description: total severity score from the Impact of Event Scale-Revised (IES-R)Measure: impact of the COVID-19 pandemic on psychiatric symptomatology Time: through study completion, an average of 2 year
Covid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.
Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 Time: 12 months
Description: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseasesMeasure: Progression of pre-existing neurological or psychiatric pathologies Time: 12 months